tm
Seeing Is Believing
tm
Seeing Is Believing
YMAB is currently covered by 9 analysts with an average price target of $12.69. This is a potential upside of $7.34 (137.2%) from yesterday's end of day stock price of $5.35.
Y mAbs Therapeutics's activity chart (see below) currently has 27 price targets and 52 ratings on display. The stock rating distribution of YMAB is 78.79% BUY, 9.09% HOLD and 12.12% SELL.
Analysts average stock forecasts to be materialized ratio is 42.98% with an average time for these price targets to be met of 130.67 days.
Highest price target for YMAB is $24, Lowest price target is $7, average price target is $15.88.
Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 21-Mar-2025. First documented stock forecast 05-May-2020.
Currently out of the existing stock ratings of YMAB, 26 are a BUY (78.79%), 3 are a HOLD (9.09%), 4 are a SELL (12.12%).
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$12
$7.17 (148.45%)
$22
25 days ago
(21-Mar-2025)
3/11 (27.27%)
$7 (140.00%)
178
Sell
$7
$2.17 (44.93%)
$11
1 months 10 days ago
(05-Mar-2025)
4/6 (66.67%)
$2.04 (41.13%)
186
Hold
$12
$7.17 (148.45%)
$10
1 months 10 days ago
(05-Mar-2025)
3/4 (75%)
$7.04 (141.94%)
114
Buy
$24
$19.17 (396.89%)
$25
5 months 4 days ago
(11-Nov-2024)
3/7 (42.86%)
$9.13 (61.40%)
367
Buy
$23
$18.17 (376.19%)
$18
7 months 5 days ago
(10-Sep-2024)
3/5 (60%)
$9.6 (71.64%)
149
What is YMAB (Y mAbs Therapeutics) average time for price targets to be met?
Which analyst has the current highest performing score on YMAB (Y mAbs Therapeutics) with a proven track record?
Which analyst has the current lower performing score on YMAB (Y mAbs Therapeutics) with a proven track record?
Which analyst has the most public recommendations on YMAB (Y mAbs Therapeutics)?
Which analyst is the currently most bullish on YMAB (Y mAbs Therapeutics)?
Which analyst is the currently most reserved on YMAB (Y mAbs Therapeutics)?
